Active, Not Recruiting
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, Dermatitis Atopic, +9 more
- Locations
-
- Allervie Clinical Research - Birmingham- Site Number : 8400050 Birmingham, Alabama, United States
- Research Solutions of Arizona- Site Number : 8400020 Litchfield Park, Arizona, United States
- Dermatology Trial Associates- Site Number : 8400027 Bryant, Arkansas, United States
- University Dermatology Trials- Site Number : 8400052 Newport Beach, California, United States